Oppenheimer首次覆盖Inhibikase Therapeutics,给予“跑赢大盘”评级及5美元目标价

美股速递
Jun 10

投资机构Oppenheimer已开始追踪研究Inhibikase Therapeutics, Inc.的股票,并在其首份研究报告中,为该公司设定了“跑赢大盘”的评级。分析师同时给出了每股5美元的目标价格。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10